Stockwinners Market Radar for September 15, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:41 EDT ARK Investment bought 92K shares of Robinhood on Wednesday

20:39 EDT ARK Investment bought 539K shares of UiPath on Wednesday

20:01 EDT SolarWinds opens South Korean entity - SolarWinds "announced the official opening of its strategic South Korean entity in Seoul, Korea, and the appointment of Ken Parker as country manager of SolarWinds in South Korea. With Parker's appointment, the newly expanded leadership team will support the company in its efforts to strengthen the brand and further solidify its position as a market leader for IT operations management software."

18:47 EDT Cisco CEO: Supply chain problems to persist through 1H22 - In an interview on CNBC's Mad Money, Chuck Robbins said Cisco's revenue has been constrained due to supply chain issues. Hybrid work is accelerating growth and will create a dynamic opportunity going forward, he added.

18:26 EDT BeiGene director sells 12.9K shares of common stock - In a regulatory filing, BeiGene disclosed that its Chief Medical Officer of Hematology, Jane Huang, sold 12.9K shares of common stock on September 13th in a total transaction size of $4.62M, reducing her stake by about 8%. Shares of BeiGene are down about 1.3% after-hours.

18:02 EDT Prenetics to go public via merger with Artisan Acquisition SPAC - Prenetics Group Limited and Artisan Acquisition Corp., a special purpose acquisition company privately founded by Adrian Cheng, announced they have entered into a definitive merger agreement. Through combining with Artisan, Prenetics will draw upon Adrian's well-diversified business portfolio across retail, hospitality, healthcare, property and other strategic businesses, providing tremendous opportunities for closely aligned partnerships and allowing Prenetics to substantially expand its platform. The transaction values Prenetics at an enterprise value of $1.25B with a combined equity value of approximately $1.7B, making Prenetics the first unicorn from Hong Kong to be publicly listed in any market. Artisan entered into a definitive agreement to combine with Prenetics. The transaction values Prenetics at an enterprise value of $1.25B with a combined equity value of approximately $1.7B. Upon completion of the transaction, estimated to be in the fourth quarter of 2021 or the first quarter of 2022, the combined company's securities will be traded on the Nasdaq under the ticker symbol "PRE". As part of the transaction, Prenetics' existing equity holders will roll 100% of their equity into PubCo, demonstrating their continued commitment to Prenetics growth strategy. Prenetics will receive proceeds of up to $459M in cash, including the contribution of up to $339M of cash currently held in Artisan's trust account, a fully committed PIPE and forward purchase agreements of $120M from Aspex, PAG, Lippo, Dragonstone, Xen Capital and others.

17:30 EDT Core & Main to acquire CES Industrial Piping Supply, terms not disclosed - Core & Main announced that it has entered into a definitive agreement to acquire substantially all of the assets of CES Industrial Piping Supply, a full service provider of HDPE products and services, based in Kansas City, Missouri. Core & Main currently serves the Kansas City region from its locations in Blue Springs, Missouri and Olathe, Kansas. "A full-service provider like CES Industrial Piping aligns with the dependable expertise we offer in fusible HDPE, which is a growth area for us. The team in Kansas City offers a one-stop shop for HDPE products, fabrication and installation, a complete package that gives customers confidence in adopting a new product," said Steve LeClair, chief executive officer of Core & Main.

17:20 EDT Pinnacle Financial CEO sells 209K shares of common stock - In a regulatory filing, Pinnacle Financial disclosed that its CEO Terry Turner sold 209K shares of common stock on September 13th in a total transaction size of $19.7M, reducing his stake by about 50%.

17:13 EDT VICI Properties and ClubCorp announce strategic deal to grow BigShots Golf - VICI Properties and ClubCorp announced that they have entered into a strategic arrangement to grow BigShots Golf, whereby VICI Properties may provide up to $80M of mortgage financing for the construction of up to five new BigShots Golf facilities throughout the United States, subject to definitive documentation. John Payne, President and Chief Operating Officer of VICI Properties, said, "We are excited to partner with ClubCorp, the leading operator of private golf and country clubs in the United States, to help grow their BigShots Golf business. ClubCorp's proven experience creating dynamic member and guest experiences throughout their country club, city and stadium club locations is highly complementary to the BigShots Golf platform and we're thrilled to serve as a financing partner. This arrangement enables VICI to continue expanding into attractive experiential sectors and new geographic markets in a prudent manner while securing additional long-term growth opportunities for VICI." "We are ecstatic to partner with VICI and expand the BigShots Golf brand to new markets across the country" said ClubCorp CEO David Pillsbury. "The golf entertainment industry continues to rapidly grow in popularity as people discover the magic of golf in a fun, non-intimidating environment. BigShots Golf is leading the way with new innovative technology, elevated dining and fun for the whole family. Our partnership with VICI will allow us to continue pursuing new market opportunities and bring the BigShots Golf experience to more communities."

17:06 EDT Aerie Pharmaceuticals falls 15% after AR-15512 phase 2b study results - Shares of Aerie Pharmaceuticals are down 15% at $13.33 after the company disclosed topline results from its Phase 2b study for AR-15512 ophthalmic solution for the treatment of patients with dry eye disease. As part of the announcement, the company also stated that "both formulations of AR-15512 were safe and well-tolerated. Ninety five percent of adverse events were mild with less than 3% of subjects discontinued due to adverse events."

17:02 EDT TuanChe announces change of auditor from PwC to Marcum Bernstein & Pinchuk - TuanChe announced the Audit Committee and the Board of Directors of the Company dismissed PricewaterhouseCoopers Zhong Tian as its independent registered public accounting firm on September 13, 2021. In connection with the change of auditor, the Company provides that: The report of PwC on the financial statements of the Company for the years ended December 31, 2020 and 2019 did not contain any adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles; and During the fiscal years ended December 31, 2020 and 2019 and the subsequent interim period through September 13, 2021 , there were no (i) disagreements with PwC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PwC, would have caused PwC to make reference to the subject matter of the disagreements in connection with its report, or (ii) reportable events. On September 13, 2021, the Board of Directors approved the engagement of Marcum Bernstein & Pinchuk LLP as the Company's new independent registered public accounting firm for fiscal year ending December 31, 2021, effective immediately.

16:46 EDT Trustmark announces $60M allocation award for Southern Community Capital - Trustmark National, a wholly-owned subsidiary of Trustmark Corporation, is pleased to announce that its subsidiary, Southern Community Capital, LLC, has been selected to receive a $60M allocation award for investment in community projects under the New Markets Tax Credit Program. Administered by the U.S. Treasury's Community Development Financial Institutions Fund, the NMTC Program was established by Congress in 2000 to spur investments in businesses and real estate projects located in low-income communities.

16:45 EDT Adobe announces payment services for Adobe Commerce - Adobe (ADBE) announced the upcoming availability of Payment Services for Adobe Commerce, "the industry's leading end-to-end commerce application for B2B, D2C and hybrid use cases. By integrating Payment Services to their digital storefronts, Adobe merchants of all sizes will soon have access to a robust, secure, and integrated payment solution that can easily be managed from their Adobe Commerce Admin, instead of having to do the work of integrating with third-party payment providers. Payment Services for Adobe Commerce will be powered by the PayPal Commerce Platform and available to Adobe merchants by the end of the year. "In today's fast-moving digital economy, organizations demand flexibility and extensibility in their commerce platform to sustain business growth and deliver seamless experiences for their customers," said Amit Ahuja, vice president, Adobe Experience Cloud Product and Strategy at Adobe. "With the addition of Payment Services, we're thrilled to expand on our already robust out-of-the-box commerce feature set to help Adobe Commerce merchants compete effectively and win in the digital-first economy." The company noted that "Easily Accept and Process Payment Methods: With Payment Services, Adobe merchants will be able to accept popular payment methods, including credit and debit cards, PayPal (PYPL) and Venmo to deliver the best checkout experience for their customers. In addition, merchants will also be able to offer PayPal pay later solutions in their storefront. According to Adobe Digital Economy Index, the use of buy now, pay later services in the first half of 2021 grew 88% compared to 2019 levels." Reference Link

16:34 EDT Surgalign names Sheryl Conley as board chair - Surgalign Holdings announced that Sheryl Conley will be appointed to the role of non-executive Chair of the Surgalign Board of Directors, effective September 14, 2021. Conley served as President and CEO of OrthoWorx, Inc., a community-based initiative that works strategically and collaboratively with the orthopedic industry, from 2012-2017.

16:31 EDT Nuance Chairman Lloyd Carney sells $653K in company shares - Nuance Chairman Lloyd Carney disclosed in a filing that he had sold 11,820 shares of company stock at $55.21 per share on September 14, for a total transaction value of $652,614.

16:31 EDT Timken sees lower sales, earnings in 2H21 - The Timken Company announced that it expects lower sales and earnings in the second half of 2021, compared to the company's prior expectations. Timken's results are being impacted by unabating customer and supply chain disruptions and related manufacturing inefficiencies, as well as continued inflationary pressures across the enterprise.Underlying customer demand and end-market momentum remain strong across most sectors, and the company expects a robust industrial market environment for the remainder of 2021 and throughout 2022. Timken is working to mitigate the impact of the supply chain challenges and inflationary pressures through improved operational efficiencies and pricing. The company continues to implement price increases and expects significant price realization in 2022. Given the unpredictability of the current environment, Timken is withdrawing its full year 2021 financial outlook, which was last updated on August 2, 2021. The company will provide further updates when it reports financial results for the third quarter of 2021.

16:18 EDT Braemar Hotels & Resorts reports August RevPar up 149% year-on-year - Braemar Hotels & Resorts reported preliminary portfolio occupancy of 59.2% for August with an average daily rate or ADR of approximately $345.88 resulting in RevPAR of approximately $204.69. This RevPAR result represents an approximate increase of 149% versus August 2020 and an approximate decrease of 12% versus August 2019. For August, Hotel Net Income was $0.9M. Comparable Hotel EBITDA for August was $9.2M, a 2% decrease versus August 2019's Comparable Hotel EBITDA of $9.3M.

16:16 EDT Ion Geophysical initiates review of strategic alternatives - Ion Geophysical announced that its board of directors has initiated a process to evaluate a range of strategic alternatives in an effort to strengthen its financial position and maximize stakeholder value as the company continues to assess conditions in the capital markets and right-size the business. These strategic alternatives include, among others, a sale or other business combination transaction, sales of assets, private or public equity transactions, debt financing, or some combination of these.

16:13 EDT Laureate Education announces special cash distribution - Laureate Education approved a plan of partial liquidation in connection with the previously disclosed sale of Walden e-Learning. Gross proceeds from the Sale, less expenses related to the Sale, will be distributed to the company's stockholders before the end of calendar year 2022. Notwithstanding the adoption of the Plan, the company expects to continue operating as a going concern and a publicly traded company. After the adoption of the Plan, the Board approved the payment of a special cash distribution pursuant to the Plan equal to $7.01 per each share of the company's Class A common stock, par value $0.004 per share, and Class B common stock, par value $0.004 per share, to each holder of record of the common stock on October 6. The Distribution is scheduled to be paid on October 29. Based on the current number of shares outstanding, the aggregate amount of the Distribution is expected to be approximately $1.29B. Gross proceeds from the Sale include $74M held in escrow and approximately $84M of restricted cash. The company intends to subsequently distribute to stockholders any net proceeds from such amounts in the form of special distributions before the end of calendar year 2022.

16:07 EDT Store Capital names Sherry Rexroad as CFO - STORE Capital announced the appointment of Sherry L. Rexroad as CFO. Ms. Rexroad will begin her employment with STORE on October 18, 2021, and will assume the position of Chief Financial Officer on November 8, 2021, in connection with the planned retirement of the company's current CFO, Catherine Long.

16:06 EDT IMA Medical, Medavail sign agreement to open four SpotRX locations in FL - MedAvail Holdings expects to open an initial four SpotRx locations in 2021 with IMA Medical Group in Florida. In-clinic SpotRx kiosks and courier home delivery will be available to patients at four IMA Medical clinic locations in central Florida. SpotRx Pharmacy is the retail pharmacy brand owned and operated by MedAvail in the United States, which deploys and operates the MedAvail MedCenters.

16:05 EDT Electronic Arts confirms 'Battlefield 2042' delayed to November 19, 2021 - Electronic Arts announced a change to the launch date of Battlefield 2042, which will now release worldwide on November 19, 2021. EA is reiterating our net bookings guidance for fiscal year 2022 provided on August 4, 2021, despite this change in launch date for Battlefield 2042. Below is a message shared by DICE Studio GM Oskar Gabrielson with the Battlefield fan community today, announcing the change to the launch date: "We've made the decision to shift the launch of Battlefield 2042. The game will now be released worldwide on November 19th, 2021. Building the next generation of Battlefield during a global pandemic has created unforeseen challenges for our development teams. Given the scale and scope of the game, we had hoped our teams would be back in our studios together as we move towards launch. With the ongoing conditions not allowing that to happen safely, and with all the hard work the teams are doing from home, we feel it is important to take the extra time to deliver on the vision of Battlefield 2042 for our players. Your enthusiasm for the game has been very inspiring. We believe in the game we're making, and we thank you for your patience as we put some finishing touches into the experience. Updates on the Open Beta will be coming later this month."

16:04 EDT Aerie Pharma's AR-15512 achieves positive topline results Phase 2b study - The company states: "Aerie Pharmaceuticals reported positive topline results of its Phase 2b clinical study, named COMET-1, for AR-15512 ophthalmic solution for the treatment of patients with dry eye disease. The randomized, double-masked, vehicle-controlled Phase 2b clinical study was conducted at 15 sites throughout the United States and evaluated the efficacy and safety of AR-15512 in patients with dry eye disease. A total of 369 patients were randomized across three arms, AR-15512, AR-15512 or AR-15512 vehicle, in each case dosed twice daily over 84 days. Patients were evaluated at Days 1, 14, 28 and 84. The COMET-1 clinical study showed greatest efficacy in the higher concentration 0.003% BID which will be advanced to Phase 3 studies."

16:02 EDT Moderna says analysis suggests COVID vaccine highly effective against variants - Moderna highlighted a new analysis suggesting that the Moderna COVID-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California and in a separate recent publication by the U.S. Centers for Disease Control and Prevention. Additionally, the company shared a new analysis of follow-up through 1 year in the Phase 3 COVE study suggesting a lower risk of breakthrough infection in participants vaccinated more recently compared to participants vaccinated last year. Manuscripts summarizing both findings have been posted to preprint servers and will be submitted for peer-reviewed publication. In a prospective cohort study at Kaiser Permanente Southern California, an analysis of 352,878 recipients of 2 doses of mRNA-1273 matched to 352,878 unvaccinated individuals found a vaccine effectiveness of 87% against COVID-19 diagnosis and 96% against COVID-19 hospitalization. The study was conducted during the emergence of the Delta variant, which was identified in 47% of cases in fully vaccinated individuals. These data have been posted to a preprint server and submitted for peer review. Recent data published by the U.S. CDC examined vaccine efficacy across nine states based on 32,867 medical encounters including 14,636 hospitalizations between June and August 2021, during the time when the Delta variant became predominant in the United States. In the analysis, the Moderna COVID-19 vaccine efficacy against COVID-19 urgent care or emergency visit was 92% and against hospitalization was 95% at a median of 96 and 106 days respectively after vaccination. Across all age groups, vaccine efficacy was reported to be significantly higher among Moderna vaccine recipients than other COVID-19 vaccines. Today, Moderna is sharing a new analysis of the incidence of breakthrough COVID-19 cases among vaccinated participants in the open-label portion of the Phase 3 COVE study between July 1, 2021 and August 27, 2021. In the analysis, 88 breakthrough cases of COVID-19 occurred in the more recently vaccinated group compared to 162 cases in the group vaccinated last year. The reduction in incidence rates for participants vaccinated more recently compared to participants vaccinated last year was 36%. A Cox proportional hazards model showed similar results after adjusting for age and risk factors for severe COVID-19. Fortunately, only 19 severe cases were observed. While not significant, there was a numerical trend towards a lower rate of severe cases in the group vaccinated more recently compared to the group vaccinated last year.

15:08 EDT Cisco says 5%-7% growth forecast does not assume 'major' acquisitions - Cisco said its 5%-7% growth forecast assumes some M&A, in keeping with its recent trends, but does not assume any "major" acquisitions. Cisco executives are conducting a Q&A session during the company's investor day meeting.

15:02 EDT Honest Company names Pete Gerstberger as chief digital and strategy officer - The Honest Company (HNST) announced that Pete Gerstberger will join the company as its chief digital and strategy officer, effective October 4. Joining Honest with more than 18 years of experience, Gerstberger's background boasts extensive digital strategy and product development, including spearheading ground-breaking initiatives at both Amazon (AMZN) and Ring (RNG).

14:41 EDT Cisco up nearly 3% in afternoon trade as investor day continues - Shares of Cisco are up $1.64, or about 3%, to $59.51 in afternoon trading as the company hosts its Virtual Investor Day 2021.

14:34 EDT Blue Apron reports board changes, collapse of multiclass voting structure - In connection with the Salzberg private placement and the proposed transactions, Matthew Salzberg, Blue Apron's co-founder and board chair, and Barry Salzberg, have resigned from the company's board of directors to focus on their other board roles and business interests. The board of directors has appointed Jennifer Carr-Smith, a current independent board member, to succeed Matthew Salzberg as board chair. Further, in connection with the rights offering and related financing transactions, certain of Blue Apron's existing holders of Class B common stock, including Matthew Salzberg, Barry Salzberg, Joseph Sanberg, and certain of their respective affiliates, have converted their shares of Class B common stock, each share of which is entitled to 10 votes per share, to shares of the company's Class A common stock, which is entitled to one vote per share. As a result of these conversions, pursuant to the company's restated certificate of incorporation, as amended, which provides for the automatic conversion of all outstanding shares of Class B common stock when the outstanding shares of Class B common stock represent less than 5% of the combined voting power of the outstanding shares of Class A common stock and Class B common stock, each outstanding share of Blue Apron's Class B common stock automatically converted into one share of Class A common stock. As a result, effective immediately, Blue Apron only has one class of common stock outstanding, Class A common stock, each share of which is entitled to one vote.

14:18 EDT Ulta Beauty gives up gains after CNBC report of Amazon beauty event

14:10 EDT ShiftPixy Labs teases 'something big' coming in tweet - ShiftPixy Labs tweeted: "Preparing ShiftPixy Labs for something BIG! #Shorts #YouTubeShorts #ShiftPixy $PIXY" Reference Link

14:05 EDT GM Defense announces award of $36.4M development contract - The U.S. Department of State has awarded GM Defense, a subsidiary of General Motors, a contract to develop and validate next generation Large Support Utility Commercial Vehicles for future fleet production in support of the Department's Diplomatic Security Service, the company announced. As part of the total development contract valued at $36.4M, GM Defense will create a purpose-built Heavy-Duty Suburban, building 10 vehicles over the next two years.

13:14 EDT North American rail traffic dropped 2.7% in week ended September 11 - The Association of American Railroads, AAR reported U.S. rail traffic for the week ending September 11. For this week, total U.S. weekly rail traffic was 468,610 carloads and intermodal units, down 1.3% compared with the same week last year. Total carloads for the week ending September 11 were 223,710 carloads, up 4.5% compared with the same week in 2020, while U.S. weekly intermodal volume was 244,900 containers and trailers, down 6% compared to 2020. North American rail volume for the week ending September 11, on 12 reporting U.S., Canadian and Mexican railroads totaled 316,174 carloads, up 2.4% compared with the same week last year, and 321,752 intermodal units, down 7.3 percent compared with last year. Total combined weekly rail traffic in North America was 637,926 carloads and intermodal units, down 2.7%. North American rail volume for the first 36 weeks of 2021 was 24,940,735 carloads and intermodal units, up 8.9% compared with 2020. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN) Greenbrier (GBX) and FreightCar America (RAIL). Reference Link

12:35 EDT DuPont to supply Betatech thermal interface material to Renault plants in France - DuPont Mobility & Materials (DD) announced that its BETATECH thermal interface material has been specified by Renault (RNSDF) for supply to its Maubeuge and Douai production facilities in northern France. Delivery of BETATECH TIM for production of electric vehicles began earlier this year. "DuPont has a long history of innovation, and we share a common vision for advancing sustainable mobility," said Gilles Le Borgne, EVP Engineering of the Renault Group. "We look forward to ongoing collaboration to develop solutions that continue to meet, and exceed, industry challenges."

12:10 EDT Great Southern Bancorp increases quarterly dividend 6% to 36c per share - The Board of Directors of Great Southern Bancorp declared a 36c per common share dividend for the third quarter of the calendar year ending December 31, 2021. This dividend represents a 6% increase from the previous quarter's dividend of 34c per common share. The dividend will be payable on October 12, 2021, to shareholders of record on September 27, 2021. This dividend represents the 127th consecutive quarterly dividend paid by the company to common shareholders, the company said in a statement.

12:00 EDT TAL Education falls -6.5% - TAL Education is down -6.5%, or -30c to $4.37.

12:00 EDT Youdao falls -11.0% - Youdao is down -11.0%, or -$1.48 to $11.98.

12:00 EDT SandRidge Energy rises 14.8% - SandRidge Energy is up 14.8%, or $1.60 to $12.41.

12:00 EDT IronNet rises 25.2% - IronNet is up 25.2%, or $5.88 to $29.20.

11:34 EDT Scientific Games discloses information on SG Lottery as part of divestiture plan - Scientific Games disclosed earlier in a regulatory filing that is providing certain information with respect to its lottery business, "SG Lottery," to certain interested parties in connection with Scientific Games' previously announced evaluation of strategic alternatives for the intended divestiture of SG Lottery. In the filing, Scientific Games said SG Lottery "predominately conducts business in North America and Europe, which contributed approximately 73% and 24% of fiscal year 2020 revenue, respectively." Revenue for the business is forecast to grow at a two-year CAGR of 13.6% to fiscal year 2022, as instant lottery participation-based revenue growth for fiscal year 2021 is estimated to be 14% in the U.S. and 23% internationally and instant lottery price per thousand tickets revenue growth for fiscal year 2021 is estimated to be 28% internationally, with Italy responsible for 36% of the European revenue growth.

11:19 EDT Nintendo says latest Switch updates includes Bluetooth audio device integration - Nintendo said the latest Nintendo Switch update is now available and includes the ability to pair Bluetooth devices for audio output. Reference Link

10:57 EDT Privately-held Amylyx submitting application to FDA for potential ALS treatment - Privately-held Amylyx Pharmaceuticals announced earlier this morning its intention to submit a New Drug Application, or NDA, to the U.S. Food and Drug Administration for AMX0035 - sodium phenylbutyrate and taurursodiol - for the treatment of amyotrophic lateral sclerosis, otherwise known as ALS. The decision by the company to submit the application in the coming months follows recent discussions with the FDA, including a pre-NDA meeting held on July 15. "We are thrilled to move toward the U.S. submission of an NDA for AMX0035 and look forward to continuing to work with the FDA. For those living with ALS, time is the most important resource, and we remain focused on advancing AMX0035 through the clinical development process as efficiently as possible," added Justin Klee, Co-CEO, Director and Co-Founder of Amylyx. "We're endlessly grateful for all of the support and efforts of ALS Finding a Cure, the ALS Association, I AM ALS, the Healey & AMG Center at Mass General and the Northeast ALS Consortium, and all CENTAUR trial participants for their critical involvement as we approach this milestone," said Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. As previously reported, Amylyx filed a New Drug Submission for AMX0035 for the treatment of ALS with Health Canada in June 2021. Amylyx also intends to submit a Marketing Authorization Application, or MAA, for AMX0035 to the European Medicines Agency's Committee for Medicinal Products for Human Use by the end of 2021 and initiate a global Phase 3 clinical trial with sites in Europe and the United States in the third quarter of 2021. In a separate press release following Amylyx's announcement, the ALS Association urged the Food and Drug Administration "to approve the treatment for all people with ALS as soon as possible." Calaneet Balas, president and CEO of The ALS Association, stated: "We are further encouraged that the FDA appears to have finally heard the loud and clear message from the ALS community that people with ALS are willing to accept greater risk to try potential treatments. We thank everyone who advocated and shared their voice with the FDA and urge the agency to approve AMX0035 swiftly." Other companies investigating potential ALS treatments include Wave Life Sciences (WVE), Seelos Therapeutics (SEEL) and BrainStorm (BCLI).

10:36 EDT National Energy Services, Ulterra announce partnership in the Middle East - National Energy Services Reunited and Ulterra Drilling Technologies announced that they have entered into an agreement to deploy and use Ulterra PDC bits across various countries in the MENA and Asia region.

10:29 EDT Triple-S, Abarca renew, expand partnership for pharmacy benefit services - Abarca, a pharmacy benefit manager, announced that Triple-S Management Corporation renewed its contract for PBM services on behalf of its managed care subsidiary, Triple-S Salud. This three-year agreement applies to the company's Medicare Advantage, Commercial, and Federal Employees Health Benefit Program lines of business. "Abarca and Triple-S have been working together for nearly a decade to deliver a better healthcare experience for members," said Jason Borschow, president and CEO at Abarca.

10:11 EDT Audacy, Cumulus Media announce content distribution partnership - Audacy (AUD) and Cumulus Media (CMLS) announced a content distribution partnership that brings Cumulus's 413 radio stations and portfolio of podcasts to the Audacy digital platform. "The addition of Cumulus's expansive portfolio of leading radio stations enhances and bolsters Audacy's position as the fastest growing digital platform for radio listeners. Audacy looks forward to building on this initial partnership with Cumulus and will continue to develop new and innovative ways to super serve our listeners," said Corey Podolsky, Vice President of Business Development, Audacy.

10:00 EDT AMC Entertainment falls -6.7% - AMC Entertainment is down -6.7%, or -$3.17 to $44.13.

10:00 EDT Advanced Drainage falls -7.5% - Advanced Drainage is down -7.5%, or -$8.43 to $104.40.

10:00 EDT SM Energy rises 9.4% - SM Energy is up 9.4%, or $1.91 to $22.17.

09:47 EDT Youdao falls -4.8% - Youdao is down -4.8%, or -65c to $12.81.

09:47 EDT Offerpad Solutions falls -6.4% - Offerpad Solutions is down -6.4%, or -71c to $10.35.

09:47 EDT Par Technology rises 7.4% - Par Technology is up 7.4%, or $4.14 to $60.15.

09:31 EDT Canadian Pacific to acquire Kansas City Southern for $31B in stock, cash - Canadian Pacific (CP) and Kansas City Southern (KSU) announced they have entered into a merger agreement, under which CP has agreed to acquire KCS in a stock and cash transaction representing an enterprise value of approximately $31B, which includes the assumption of $3.8B of outstanding KCS debt. The transaction, which has the unanimous support of both boards of directors, values KCS at $300 per share, representing a 34% premium, based on the CP closing price on August 9, the date prior to which CP submitted a revised offer to acquire KCS, and KCS' unaffected closing price on March 19. The combined company wwill be operating approximately 20,000 miles of rail, employing close to 20,000 people, and generating total revenues of approximately $8.7B based on 2020 actual revenues. The CP-KCS combination is expected to create jobs across the joined network. Following the closing into a voting trust, common shareholders of KCS will receive 2.884 CP shares and $90 in cash for each KCS common share held. Preferred shareholders will receive $37.50 in cash for each KCS preferred share held. The fixed exchange ratio implies a price for KCS of $300 per share, representing a 34% premium, based on the CP closing price on August 9 and KCS' unaffected closing price on March 19. Immediately following the closing into trust, KCS common shareholders are expected to own 28% of CP's outstanding common shares, providing the ability to participate in the upside of both companies' growth opportunities. Following final regulatory approval by the U.S. Surface Transportation Board, or STB, KCS shareholders would also reap the benefits of synergies resulting from the combination. The combined company is expected to create annualized synergies of approximately $1B over three years. The combination is expected to be accretive to CP's adjusted diluted EPS in the first full year following CP's acquisition of control of KCS, and is expected to generate double-digit accretion upon the full realization of synergies thereafter. To fund the stock consideration of the merger, CP will issue 44.5M new shares. Consistent with the previously announced transaction, the cash portion will be funded through a combination of cash-on-hand and raising approximately $8.5B in debt, for which financing has been committed. As part of the merger, CP will assume approximately $3.8B of KCS' outstanding debt. Following the closing into trust, CP expects that its outstanding debt will be approximately $20B. Pro forma for the transaction, CP estimates its leverage ratio against 2021E street consensus EBITDA to be approximately 3.9x with the assumption of KCS debt and issuance of new acquisition-related debt. In order to manage this leverage effectively, CP will continue to temporarily suspend its normal course issuer bid program, and expects to produce approximately $7B of levered free cash flow over the next three years. CP estimates its long-term leverage target of approximately 2.5x to be achieved within 24 months after closing into trust. The STB review of CP's proposed control of KCS is expected to be completed in the second half of 2022. Upon obtaining control approval, the two companies will be integrated fully over the ensuing three years. Following STB approval of the CP's control of KCS, CP CEO Keith Creel will serve as the CEO of the combined company. The combined entity will be named Canadian Pacific Kansas City. Calgary will be the global headquarters of CPKC, and Kansas City, Missouri will be the U.S. headquarters. The Mexico headquarters will remain in Mexico City and Monterrey. CP's current U.S. headquarters in Minneapolis-St. Paul will remain an important base of operations. Four KCS Directors will join CP's expanded board at the appropriate time.

09:28 EDT Canadian Pacific, Kansas City Southern confirm merger agreement - Canadian Pacific (CP) and Kansas City Southern (KSU) announced they have entered into a merger agreement, under which CP has agreed to acquire KCS in a stock and cash transaction representing an enterprise value of approximately $31B, which includes the assumption of $3.8B of outstanding KCS debt. The transaction, which has the unanimous support of both boards of directors, values KCS at $300 per share, representing a 34% premium, based on the CP closing price on August 9, the date prior to which CP submitted a revised offer to acquire KCS, and KCS' unaffected closing price on March 19. Following STB approval of the CP's control of KCS, Keith Creel will serve as the CEO of the combined company. The combined entity will be named Canadian Pacific Kansas City. Calgary will be the global headquarters of CPKC, and Kansas City, Missouri will be the U.S. headquarters. The Mexico headquarters will remain in Mexico City and Monterrey. CP's current U.S. headquarters in Minneapolis-St. Paul will remain an important base of operations. Four KCS Directors will join CP's expanded Board at the appropriate time, bringing their experience and expertise in overseeing KCS' multinational operations.

09:23 EDT Columbia Sportswear announces multi-year sponsorship with USA Curling - Columbia Sportswear announces a multi-year sponsorship with USA Curling. Columbia will be working closely with the USA Curling National Team Program, including the Men's, Women's, Junior, and Wheelchair National Teams, and debuting new competitive uniforms on Curling Night in America airing on the NBC Sports Network starting September 19.

09:22 EDT Exact Sciences says expanded primary care sales team by hiring Pfizer employees - Exact Sciences (EXAS) announced it has expanded its primary care sales team to increase adoption of Cologuard and its pipeline of other cancer screening tests. "In late August, Pfizer (PFE) announced internally that it decreased the number of sales positions supporting its Internal Medicine therapeutic area. The displaced employees had been promoting Cologuard under an agreement between Exact Sciences and Pfizer. Exact Sciences offered the displaced Pfizer sales representatives opportunities to join its team in full-time sales roles promoting Cologuard, and the vast majority of those offers were accepted. Exact Sciences completed an expedited hiring process and onboarded approximately 400 sales representatives in September, increasing the size of its primary care field sales team to more than 850 representatives. Exact Sciences expects the newly hired representatives to be more productive as its own employees, fully dedicated to its mission to eradicate cancer, and better able to coordinate interactions with health care providers as one team. Exact Sciences' newly expanded team is in the field and interacting with health care providers in person, focused solely on Cologuard initially. Pfizer is currently promoting Cologuard with a smaller team under the Promotion Agreement; however, due to its recent COVID-19 internal policies, which are different from Exact Sciences', Pfizer is not making in-person sales calls in 41 states. Exact Sciences is in discussions with Pfizer that could result in material changes to the Promotion Agreement and its relationship with Pfizer," the company stated in a regulatory filing.

09:19 EDT Amazon Prime, Anghami collaborate in Saudi Arabia, UAE on Anghami Plus - Amazon and Anghami announced that Amazon Prime members in Saudi Arabia and the UAE can enjoy an exclusive six-months free offer on Anghami Plus, Anghami's premium paid tier, with their Prime membership. Delivering the ultimate music experience from Anghami, Prime members in Saudi Arabia and the UAE will receive a free six-month subscription to Anghami Plus, followed by 50% off the subscription fee for the next six months. Earlier on August, 3 2021, Vistas Media Acquisition Company Inc. and Anghami announced the submission of a confidential Draft Registration Statement on Form F-4 to the U.S. Securities and Exchange Commission with respect to their proposed business combination.

09:17 EDT Codorus Valley Bancorp appoints Craig Kauffman as president, CEO - Codorus Valley Bancorp announced that as part of the Company's long-term succession plan, the Board of Directors has appointed Craig Kauffman President and CEO of the Company effective October 1, 2021. Mr. Kauffman will succeed Larry Miller, who served the Company as President and CEO since 1986. Mr. Miller will serve as Executive Chair of the Company and will continue in his role as Executive Chair of PeoplesBank until December 31, 2021. Kauffman is currently the EVP and COO of the Company and has been a member of the Board of Directors since 2019.

09:10 EDT CohBar appoints Joanne Yun to board of directors - CohBar announced the appointment of Joanne Yun, Ph.D. as an independent director on the company's Board, effective September 14, 2021. DYun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry. Yun is a partner at Egon Zehnder and is currently a member of the firm's Health Practice. In addition to her board and executive leadership work for global pharmaceutical and biotechnology companies, Yun leads the Research & Development segment of Egon Zehnder's Health Practice.

09:08 EDT Progress Software announces availability of Progress Sitefinity DX 14.0 - Progress announced the availability of Progress Sitefinity DX 14.0. This agile, flexible and extensible platform allows organizations to create an ideal digital experience platform tailored to their unique needs and objectives with new capabilities for low-code integration and chat-driven engagement, as well as enhanced headless content delivery.

09:08 EDT CME Group to launch E-mini Russell 2000 Monday and Wednesday Weekly options - CME Group will launch E-mini Russell 2000 Monday and Wednesday Weekly options on October 4, pending regulatory review. These new options contracts will complement the existing Friday Weekly, End-of-Month and Quarterly options on Russell 2000 futures. Similar to their counterparts, these new weekly options will be European-style, with a 4 p.m. ET expiry on Mondays and Wednesdays. These contracts are E-mini sized option contracts with a $50 multiplier.

09:06 EDT CNH Industrial, Nikola sign MoU with Hamburg Port Authority - IVECO, the commercial vehicles brand of CNH Industrial (CNHI) and Nikola Corporation (NKLA), signed a Memorandum of Understanding, or MoU, with Hamburg Port Authority AoR during the inauguration of their joint-venture manufacturing facility in Ulm, Germany. The agreement states their joint intent to partner in two phases encompassing up to 25 Nikola Tre battery-electric vehicles, or BEVs, for delivery to the Port throughout 2022. The first phase involves testing of the Nikola Tre BEVs at the port for transport and logistics operations together with charging solutions. A more definitive second phase in the project partnership plans to see the full integration of the BEV vehicles in port operations, installation of charging infrastructure and on-site service support including major suppliers. The vehicles provided for these two phases will be the US version of the Nikola Tre with special permissions for in-port operation. Nikola CEO Mark Russell said, "Nikola is also working on a similar program in the United States. These types of landmark agreements continue to reinforce the global shift we are seeing toward a new zero-emission future."

09:05 EDT Ortelius opposes Capital Senior Living deal with Conversant Capital - Ortelius Advisors which owns approximately 12.7% of the outstanding common stock of Capital Senior Living Corporation released a detailed presentation regarding its opposition to the Company's proposed financing transactions with Conversant Capital . Ortelius urges Capital Senior Living's stockholders to vote against all of the Company's proposals on the GOLD proxy card at the upcoming meeting of stockholder on October 12. Peter DeSorcy, Managing Member of Ortelius, commented: "Our detailed presentation demonstrates that Capital Senior Living's Board of Directors ran a deeply-flawed process for assessing the Company's capital needs and financing options. Our analysis indicates that over the course of the first half of 2021, the Board of Directors overlooked the industry's recovery, the Company's improving fundamentals and a world awash in trillions of dollars in liquidity at historically low interest rates and credit spreads. This is why stockholders are now being asked to vote on a series of costly, dilutive and unnecessary transactions that would effectively hand control of the business to Conversant at a material discount. Fortunately, stockholders can reject the Proposed Transactions at the upcoming Special Meeting and put the Company in a position to evaluate what we believe are readily available and viable financing alternatives. As outlined in our presentation, Ortelius believes there are superior alternatives for the Company to consider if the Proposed Transactions are voted down. We are prepared to participate as a backstop and subscribe well beyond our pro rata share in a new equity rights offering, provided that such an offering is decoupled from the Proposed Transactions. Ortelius views this as a clear path to raising up to $70 million in capital - a sum that we believe can more than satisfy Capital Senior Living's near-term needs. We encourage our fellow stockholders to review our full presentation to assess this path and other options."

09:05 EDT Hilton, Mars Petcare partner on pet-friendly travel - Hilton and Mars Petcare announced they are teaming up to set a new standard for pet-friendly travel. Leveraging insights from Mars Petcare's BETTER CITIES FOR PETS program, Hilton's Extended Stay brands, Homewood Suites by Hilton and Home Suites by Hilton will implement pet-focused programming and benefits in the U.S. and Canada to become a pet hero for guests. Additionally, by January 1, 2022, Homewood Suites will join Home2 Suites to become a 100% pet-friendly brand across its portfolio of hotels and both brands will introduce consistent pet fees, starting at $50 per stay.

09:04 EDT EnWave says Scitek acquires 10kW REV machine from Helius - EnWave's exclusive channel partner representing REV technology in Australasia has agreed to purchase the 10kW non-GMP REV machine from Helius Therapeutics for the purposes of showcasing the technology's capabilities to a plethora of new potential licensees in both the food and cannabis verticals. Scitek will install their 10kW machine close to Melbourne, Australia and make it available to any interested third-parties for testing and product development. Concurrently with the transfer of machine ownership to Scitek, Helius and EnWave agreed to terminate their license agreement. Former Helius management purchased a non-GMP REV machine that is not compatible with their full GMP facility classification.

09:04 EDT VirnetX names Kathy Allanson as CFO, Dr. Victor Larson as CTO - VirnetX (VHC) announced that it has promoted Dr. Victor Larson to Chief Technical Officer and has hired Kathy Allanson as its new CFO. Dr. Victor Larson is promoted to CTO from his previous position of Vice President of Research and Development. Dr. Larsen is a co-inventor of the VirnetX technologies. Prior to joining VirnetX, Dr. Larson worked for over 20 years doing system engineering, software design and technical program management under contract to many branches of the Department of Defense and the intelligence community. Allanson's prior employment includes positions at Arthur Andersen LLP and The Walt Disney Company (DIS). Dr. Robert Dunham Short III continues as VirnetX Chief Scientist and Board of Directors member.

09:02 EDT MGM Growth increases quarterly dividend to 52c per share - MGM Growth Properties declared a quarterly cash dividend of 52c per Class A common share for Q3. On an annualized basis, the dividend of $2.08 represents an increase of 2c per share. The dividend will be payable on October 15 to shareholders of record as of the close of business on September 30.

09:01 EDT Zoom Video announces reseller partner program for Zoom Phone BYOC - Zoom Video Communications announced that its reseller partners will have the opportunity to sell Zoom Phone Bring Your Own Carrier licenses. They will also be able to connect customers who use enhanced cloud peering to access PSTN to Zoom Phone Provider Exchange, a new way to discover providers and follow a self-service journey to provision phone numbers securely. Zoom is currently running a pilot program for select resellers that meet the requirements to sell Zoom Phone BYOC and expects to welcome a wider pool of resellers by the end of the year. Previously, only Zoom Master Agents had the opportunity to refer deals for Zoom Phone and Zoom Phone BYOC. Now Zoom's reseller partners from around the world who meet the requirements and qualify will be authorized to resell Zoom Phone BYOC.

08:49 EDT ME2C completes initial testing of Rare Earth Element Technology - Midwest Energy Emissions announced that Pennsylvania State University's College of Earth and Mineral Sciences has completed the initial round of testing to evaluate the company's new Rare Earth Element Technology. "The initial results received by Penn State's College of Earth and Mineral Sciences will lead to the further testing and development of this emerging technology focused on rare earth capture, as well as the cleanup of coal ash ponds and wastewater from coal-fired power plants," stated Richard MacPherson, CEO of ME2C Environmental. "We expect to have Penn State continue with the evaluation of the technology's extraction capacity of certain rare earth elements as well as its regeneration potential and other factors necessary to move forward with pilot scale testing. The careful vetting of this technology was thoughtfully planned as we began down this path nearly two years ago in collaboration with Dr. Scott Drummond. We believe that the cleanup of coal ash ponds and runoff heavily contaminated with coal refuse is the leading environmental concern facing the U.S. and the energy sector today and we are hopeful to bring a cost-effective, environmentally sound solution to market as we move into early 2022."

08:47 EDT ElectraMeccanica to launch customer deliveries of SOLO EV - ElectraMeccanica Vehicles announced that it is starting customer deliveries of its single-occupant, three wheeled, all electric vehicle, the SOLO. The company will officially begin delivering keys to customers at a special launch event scheduled for October 4th in Los Angeles. Deliveries to other reservation holders and customers will steadily increase as production continues to ramp. ElectraMeccanica began production of the SOLO EV a year ago with its manufacturing partner and strategic investor, Zongshen Industrial Group. These initial production vehicles were primarily used for retail expansion, test drive events, fleet demonstrations, marketing and final on-road engineering enhancements. "This is the 'Key Moment' we've all been eagerly anticipating: We're announcing the delivery of the first SOLOs to excited customers," said Paul Rivera, President and CEO of ElectraMeccanica. "This is a major milestone for ElectraMeccanica and the EV industry, and I'm incredibly proud of the work our entire team and partners have put in to make this day a reality." ElectraMeccanica has a retail footprint in five western states: Arizona, California, Colorado, Oregon, and Washington. The SOLO is a purpose-built, three-wheeled, all-electric solution for the urban environment.

08:45 EDT Predictive Oncology appoints Raymond Vennare to board of directors - Predictive Oncology announces that Raymond Vennare was elected to the Board of Directors, pursuant to action of the Board effective September 13, 2021. Currently, Vennare is Chief Executive Officer and Chairman of the Board of Cvergenx, a genomic informatics company developing decision-support tools for radiation oncology.

08:42 EDT Quanta's Medolife Rx completes bi-annual visit from MOE to scorpion reservation - Medolife Rx, which is a majority owned subsidiary of Quanta, announced that the company received positive feedback from its bi-annual visit by the Ministry of Environment, or MOE, of the Dominican Republic, or DR, to its scorpion reservation in the local Neyba province. The formal visit resulted as part of the joint venture partnership between Medolife and the MOE by the surveying commission, where the company was able to meet certain contract points of the agreement. The Company has been engaged with the MOE of the DR in a joint venture on the development of a scorpion reservation and investigation on endemic wildlife in the Neyba province since 2008. The visit took place on September 11, 2021, where The Director of Biodiversity of the MOE and his team visited the facility and shared an overall positive assessment of the facility. This assessment led to the satisfaction of the purpose of the visit and the renewal of the ongoing relationship between the MOE and Medolife. The scorpion reservation serves as the Company's main source of peptide production that is used in most of its pharmaceutical and nutraceutical products.

08:41 EDT IronNet up about 14% in pre-market trading at $26.64 per share - Shares of IronNet are up about 14% at $26.64 in pre-market trading following yesterday's 20.3% advance. The stock is the highest trending ticker on WallStreetBets Reddit thread and is also in the top-10 on StockTwits in terms of message volume over the past 24 hours.

08:40 EDT Coherus, Junshi announce results from Phase 3 study of toripalimab - Coherus BioSciences and Shanghai Junshi Biosciences announced publication of a cover article in the September issue of Nature Medicine featuring clinical data from the pivotal study "JUPITER-02", a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, or NPC. Titled "Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial," the paper highlights that the addition of toripalimab to standard of care gemcitabine-cisplatin chemotherapy as a first-line treatment for patients with recurrent or metastatic NPC provided superior progression free survival compared to GP alone, and with a manageable safety profile. The impact of the addition of toripalimab on PFS was demonstrated in patients regardless of PD-L1 expression status. Although overall survival data were not yet mature, as of February 18, 2021, a 40% reduction in risk of death was observed in the toripalimab arm compared to the placebo arm. The incidence of grade greater than or equal 3 to treatment emergent adverse events, TEAEs leading to discontinuation of toripalimab/placebo, and fatal TEAEs was similar between both arms. Immune-related adverse events and Grade greater than or equal to 3 irAEs were more frequent in the toripalimab arm. The full results can be found in the on-line edition of Nature Medicine. A biologics license application has been submitted to the U.S. Food and Drug Administration for toripalimab in combination with gemcitabine and cisplatin for first-line treatment for patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for second-line or above treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.

08:39 EDT Turtle Beach becomes official sponsor of UCSD Esports - Turtle Beach announced it has become an official sponsor of UCSD Esports and the primary gaming accessories provider for UC San Diego's new Triton Esports Center, TEC. Through the new partnership, Turtle Beach will provide UC San Diego's competitive esports teams with premier gaming accessories. Turtle Beach is providing its legendary Elite Pro 2 competitive gaming headset and best-selling Stealth 600 wireless console headsets. Additionally, ROCCAT - Turtle Beach's award-winning PC brand - is providing an assortment of its latest precision PC equipment like the Kone Pro mice, Vulcan TKL Pro keyboards, Elo 7.1 USB PC headsets, and more. Turtle Beach is also allocating funds to support the UCSD Esports scholarship program to help student-athlete gamers study at a world class institution and compete in the dynamic world of collegiate esports.

08:38 EDT Jaguar Health unit Napo gets ODD for crofelemer to treat SBS-IF - Jaguar Health announced that the European Medicines Agency,EMA, has confirmed that the Orphan Drug Designation, ODD, application for crofelemer submitted by Napo the Italian subsidiary of Napo Pharmaceuticals for the indication of short bowel syndrome with intestinal failure, SBS-IF, has been accepted for review. Confirmation from the EMA that the submission is accepted starts the formal review process of the application by the EMA's Committee for Orphan Medicinal Products COMP. Napo EU's initial focus is on pursuing the EMA's conditional marketing authorization pathway in Europe for crofelemer for this important orphan disease indication. "We are very happy that the orphan drug designation application for crofelemer for SBS-IF is now with the EMA," stated Lisa Conte, Jaguar's president and CEO and Napo EU board member. "Looking forward, upon receipt of a positive opinion from the COMP, crofelemer will be eligible for granting of orphan drug designation by the EMA for this indication. Receipt of orphan drug designation would support a conditional marketing authorization pathway for SBS-IF, which provides a fast-track review of a medicine that fulfills an unmet medical need."

08:36 EDT ZK International Group invests additional $10M in Maximbet.com - ZK International Group is pleased to announce that it has made an additional investment of $10M in Maximbet.com, increasing its ownership stake in the rapidly-growing sports betting and casino operator to 15.73%. Maximbet is a privately-held multi-state and globally licensed sports betting and casino operator hyper-focused on capitalizing on the expansion of the recently legalized sports betting market in the United States. The U.S. market is seeing rapid growth with year over year transactions increasing by 126%. Cathie Wood's ARK Investment Management LLC believes that total wagers placed in the U.S. could increase 9x to $180B by 2025.

08:35 EDT Atai Life Sciences increases loan in principal by $6M to IntelGenx - atai Life Sciences announced it has entered into an amended and restated loan agreement with strategic partner IntelGenx Technologies Corp. to support IntelGenx's conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock Exchange. Completion of the uplisting and the commencement of trading of IntelGenx's common shares, 8% convertible debentures with a maturity date of June 30, 2022, and share purchase warrants expiring on February 11, 2023 is subject to the satisfaction by IntelGenx of all of the final conditions of listing. atai has agreed to increase the principal amount of its outstanding US$2,500,000 loan to IntelGenx by an additional $6,000,000, with $3,000,000 to become available to IntelGenx in each of January 2022 and January 2023, subject to customary conditions. The loan is in addition to atai's previously announced initial equity investment of an approximately 25% interest in IntelGenx. The loan bears interest at a rate of 8% per annum, payable at maturity, and matures in January 2024. The borrower under the secured loan is IntelGenx's wholly-owned subsidiary, IntelGenx Corp., and the loan is guaranteed by IntelGenx. As part of the strategic partnership, IntelGenx partnered exclusively with atai to develop formulations of compounds for the prevention or treatment of mental health diseases or disorders, including compounds that have psychedelic, entactogenic and/or oneirophrenic properties. atai agreed to increase the loan principal in part on the basis of early data generated from its ongoing feasibility studies conducted with IntelGenx.

08:34 EDT Roblox reports August DAU 48.2M, up 32% - Roblox released its August key metrics. Daily active users, or DAU, were 48.2M, up 32% from August of last year and up 4% from 46.6M DAUs in July. Hours engaged were 4B, up 32% year over year and up 5% from 3.8B hours in July. Bookings are estimated to be between $219M and $222M, up 29%-31% year over year. Average Bookings per DAU are estimated to be between $4.54 and $4.60, down 1% - 2% year over year. Revenue is estimated to be between $167M and $170M, up 98%-102% year over year.

08:33 EDT Workhorse Group announces withdrawal of USPS bid protest - Workhorse Group announced that it has withdrawn its United States Postal Service bid protest complaint filed in the United States Court of Federal Claims. "After attending the recent Advanced Clean Transportation show, we are excited about the multiple business opportunities ahead for last-mile delivery truck and drone system technologies," said Workhorse CEO Rick Dauch. "These opportunities include several commercial industry markets as well as a broad array of initiatives designed to modernize and electrify government funded and owned vehicle fleets across the country at the federal, state and city level. Since I joined the company six weeks ago, we have been conducting a deep and intensive overview of all aspects of our business, including an examination of the history of our USPS bid and subsequent protest filing. The federal government has announced its intention to replace its fleet with electric vehicles, and we believe that the best way for us to work with any governmental agency is through cooperation, not through litigation. By withdrawing our protest, we can also better focus our time and resources on initiatives that we expect will be more productive for our company."

08:32 EDT Albireo Pharma announces Bylvay now available in Germany - Albireo Pharma announced that Bylvay, the first drug approved in Europe for the treatment of all types of progressive familial intrahepatic cholestasis, or PFIC, is now available by prescription to patients in Germany. Bylvay is also approved in the U.S. for the treatment of pruritus in all types of PFIC. Bylvay is now available through retail pharmacies. Sales promotion has already begun, with Albireo commercial staff covering the key centers to inform them of the availability of Bylvay for the treatment of PFIC and the patient support services available. Albireo has launched Bylvay in the U.S. and is working to commercialize Bylvay in other European countries. Bylvay is currently being evaluated by a number of reimbursement agencies in Europe. Bylvay is currently being evaluated in the ongoing PEDFIC 2 open-label trial in patients with PFIC, ASSERT Phase 3 study for Alagille syndrome and in the BOLD Phase 3 study for patients with biliary atresia. The ASSERT and BOLD studies remain on track to report topline data in 2022 and 2024 respectively.

08:28 EDT Heineken partners with Daniel Craig for commercial concept - Heineken reveals a new commercial concepted in collaboration with Daniel Craig called 'Worth The Wait', which celebrates the highly anticipated release of the new James Bond film No Time To Die. The advert shows Daniel Craig waiting patiently for the first satisfying sip of an ice-cold Heineken beer, an ode to fans who have eagerly awaited the next installment of the franchise and showing that the best things come to those who wait.

08:22 EDT IntelGenx receives $6M in additional loans from Atai, approval to graduate TSX - IntelGenx Technologies (IGXT) has entered into an amended and restated secured loan agreement with atai Life Sciences (ATAI) pursuant to which atai has made two additional term loans available to IntelGenx in the amount of $3,000,000 each, which will mature on January 5, 2024. The New Loans will be made on January 7, 2022 and January 6, 2023, respectively, subject to the satisfaction of customary conditions. The Loan Agreement also extends the maturity date for the current loans, in an aggregate amount of $2,500,000, to January 5, 2024. The obligations under the New Loans are guaranteed by the Company. The Company also announces that it has received conditional approval from the Toronto Stock Exchange to graduate from the TSX Venture Exchange and list its shares of common stock, its 8% convertible debentures with a maturity date of June 30, 2022, and its share purchase warrants expiring on February 11, 2023, on the TSX. Final approval of the listing is subject to the Company meeting certain requirements of the TSX. The Company will make a further announcement once the TSX has issued a bulletin confirming the date on which trading on the TSX will commence. In connection with the listing on the TSX, the Company will apply to voluntarily delist its Common Shares, debentures and warrants from the TSX Venture Exchange to be effective as of the date the Common Shares, debentures and warrants commence trading on the TSX.

08:19 EDT Home Bancshares to acquire Happy Bancshares in all-stock merger - Home BancShares and Happy Bancshares announced that they have entered into a definitive merger agreement pursuant to which Home BancShares will acquire Happy Bancshares in an all-stock merger, with Home BancShares as the surviving entity. The combination grants Home BancShares access to the high growth Texas market and establishes the combined entity as a dominant Southern institution with the opportunity to leverage each company's track record of performance, integration and leadership. The combination positions Home BancShares to expand further into Texas and potentially acquire additional institutions over time. Under the terms of the definitive merger agreement, which was unanimously approved by the Boards of directors of both companies, Happy Bancshares shareholders upon closing of the merger will receive 2.17 shares of Home BancShares stock for each share of Happy Bancshares they own and will begin receiving quarterly dividends declared by Home BancShares. Based on a volume-weighted average closing price per share of Home BancShares stock of $21.77 during the 20-trading-day period ending on September 13, 2021, the per share consideration value is $47.24 and the aggregate transaction value is approximately $919 million. The transaction is consistent with Home BancShares' M&A track record and is expected to be immediately triple accretive: resulting in increases to earnings per share of 5.5% and 9.2% for 2022 and 2023, respectively; book value per share of 5.1% and tangible book value per share of 1.5%2. Following the completion of this transaction, Home BancShares will continue to have a robust capital position along with an improved operating profile. The pro forma bank will be approximately $23.3 billion in assets, $13.4 billion in loans and $18.7 billion in deposits and will be one of the 75 largest banks headquartered in the United States3. Home BancShares will continue to be headquartered in Conway, Arkansas and operate as Centennial Bank in its current markets. As part of the transaction, Home BancShares will add J. Pat Hickman, current Happy Bancshares Chairman, to its Board of Directors. Happy Bancshares CEO, Mikel Williamson will join the Centennial Bank executive team while additional Happy State Bank executives are to maintain leadership roles in Texas markets. Following completion of the merger, branches located in Texas will be branded Happy State Bank, a Division of Centennial Bank. The merger is expected to close early in the first quarter of 2022, subject to satisfaction of customary closing conditions, including customary regulatory approvals and approval by the shareholders of each company.

08:18 EDT Fate Therapeutics announces publication of FT538 preclinical data - Fate Therapeutics announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled "Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy". "The NK cell community has long sought to improve NK cell activation, cytotoxicity, functional persistence, and tumor targeting for cancer immunotherapy. Our preclinical data demonstrate that the synthetic features of FT538 uniquely harness all these therapeutic attributes and significantly improve NK cell anti-tumor activity," said Bob Valamehr, Ph.D., Chief Research and Development Officer of Fate Therapeutics. "We are excited to bring FT538 to patients for off-the-shelf treatment of hematologic malignancies and solid tumors, and to continue to leverage its multiplexed engineered backbone as the foundation for development of multi-antigen, CAR-targeted product candidates." The peer-reviewed paper describes preclinical studies showing that FT538 shares metabolic, transcriptional, and functional features with adaptive NK cells. The data demonstrate that FT538 persists in vivo at high levels for more than six weeks in the absence of cytokine support after adoptive transfer, whereas adoptively-transferred peripheral blood NK cells required the co-infusion of either IL-2 or IL-15 to achieve low-level persistence for up to two weeks.

08:15 EDT Oramed's Phase 2 oral insulin NASH trial surpasses 50% enrollment - Oramed has enrolled over 50% of patients planned for its Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis. Patients continue to be screened at sites in the U.S. and Israel. The double-blind, multi-center trial is assessing the safety and potential efficacy of ORMD-0801 in Type 2 diabetes patients with NASH. Efficacy endpoints including percentage change in liver fat content, liver fibrosis, and liver steatosis from baseline will be measured via MRI-PDFF following 12 weeks of dosing.

08:13 EDT Celularity appoints Andrew Pecora as President - Celularity announced the appointment of Andrew Pecora, M.D., F.A.C.P., C.P.E., as President effective today. Reporting to Robert Hariri, M.D., Ph.D., Chairperson and Chief Executive Officer, Pecora will provide senior leadership to advance Celularity's clinical pipeline toward U.S. Food and Drug Administration approval, including responsibility for preclinical and clinical development and regulatory affairs. Pecora previously served as President of the Physician Enterprise, Chief Innovations Officer, and the Institutional Research Official of Hackensack Meridian Health. Pecora is Founder and serves as Chairman of Cota.

08:12 EDT Magenta Therapeutics gets clearance for MGTA-117 targeted conditioning trial - Magenta Therapeutics, announced that its Investigational New Drug IND application for MGTA-117 is active with the U.S. Food and Drug Administration FDA. The company expects to open the Phase 1/2 clinical trial in Q4 2021 to evaluate its MGTA-117 antibody-drug conjugate ADC targeted conditioning program. "We are very pleased that our collaboration with the FDA has resulted in the clearance of the MGTA-117 IND. We have addressed the FDA's request for a bioassay to be incorporated into the clinical trial protocol," said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. "Improving conditioning treatments is essential for broadening patient accessibility to the curative potential of stem cell transplant and gene therapies. We have designed MGTA-117 specifically to replace toxic radiation and chemotherapy-based conditioning agents used in current medical practice. This program holds significant potential for patients across several disease areas." The multi-center, open label Phase 1/2 clinical trial with single-dose escalating cohorts will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MGTA-117 as a single agent in relapsed/refractory AML and MDS patients. Magenta will continue to engage with the FDA to transition the trial to the intended primary target population of hematopoietic stem cell transplant-eligible AML and MDS patients. In addition, Magenta has planned gene therapy clinical trial collaborations with AVROBIO and Beam Therapeutics to evaluate the potential utility of MGTA-117 for conditioning gene therapy patients without the use of non-selective busulfan or other toxic chemotherapies.

08:11 EDT PowerFleet selected by Hyundai Translead to launch HT LinkSense Platform - PowerFleet (PWFL) announced Hyundai Translead (HYMTF) will be leveraging the PowerFleet LV-300 trailer tracking gateway solution to launch HT LinkSense. "Through this integration with PowerFleet, HT LinkSense will be able to provide fleet managers with the flexibility to choose sensor and telematics solutions that meet their needs," the company said. Initially, the HT LinkSense solution will be available for the Hyundai Translead dry van line, but future expansion into refrigerated, flatbed, chassis and aftermarket products is planned. The PowerFleet LV-300 asset tracking solution provides continuous real-time visibility while in transit, and more accurate arrival and departure information to better plan supply chain resource allocation. "We are honored that Hyundai Translead has selected PowerFleet as a key part of its HT LinkSense solution for trailers," explains Chris Wolfe, CEO of PowerFleet. "Our integrated logistics solutions will enable customers to access a more holistic view of their trailers and freight status by capturing critical sensor and telematics data. By leveraging our trusted telematics platform, analytics and real-time reporting capabilities, Hyundai Translead will raise the bar with its' HT LinkSense offering by delivering high-value asset information to the transportation industry."

08:09 EDT Jounce Therapeutics appoints Jigar Raythatha to board of directors - Jounce Therapeutics announced the appointment of former CEO of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors.

08:08 EDT Equinix appoints Ron Guerrier to Board of Directors - Equinix (EQIX) announced the appointment of Ron Guerrier to the Equinix Board of Directors. His appointment brings the number of directors on the Equinix Board to nine. With a career in the information technology sector that spans more than a quarter century, Guerrier is the chief information officer of HP Inc (HPQ).

08:07 EDT electroCore announces patent expanding claims related to nVNS therapy - electroCore announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methods integrated with, or coupled to, smartphones that allow patients to self-treat medical conditions, such as migraine headache, by electrical non-invasive stimulation of nerves. The '102 patent is the 8th US patent issued to ECOR in the company's mobile connectivity platform, with additional US and International matters pending. electroCore is building a portfolio of Intellectual Property around smartphone-integrated and smartphone connected non-invasive therapy. This IP may provide a foundation for combining the company's clinically proven non-invasive Vagus Nerve Stimulation with application-based digital health platforms that could enable health care providers to use Remote Patient Monitoring or Remote Therapeutic Monitoring reimbursement codes. That combination, in turn, may enable future business models and revenue streams for the company's products.

08:06 EDT Aemetis Biogas signs utility pipeline agreement with PG&E - Aemetis (AMTX) announced that its subsidiary Aemetis Biogas has signed the Standard Renewable Gas Interconnection Agreement, or SRGIA, with the Pacific Gas & Electric Company (PCG) and funded the final $1.2M payment for installation of PG&E's interconnection equipment to deliver renewable natural gas, or RNG, into the utility gas pipeline in Q4 2021. The PG&E RNG interconnect equipment has already been fabricated onto modular units that are now scheduled to be delivered to the Keyes plant and installed during the next three months. When the interconnection unit is completed, the RNG produced by the Aemetis Biogas Central Diary Digester Project will be delivered into the Pacific Gas & Electric natural gas pipeline for sale to customers throughout California as transportation fuel. Aemetis has already built and currently operates two dairy biogas digesters, on-site dairy gas upgrading and pressurization facilities, and a four-mile biogas pipeline connecting the dairies to the Aemetis Keyes ethanol plant. The centralized biogas cleanup and onsite RNG fueling facilities at the Keyes plant are currently under construction for completion in Q4 2021, and the construction of 15 additional dairy biogas digesters are in progress for completion during 2022. When fully built out, the planned 52 dairies in the Aemetis biogas project are expected to capture more than 1.4M MMBtu of dairy methane and reduce greenhouse gas emissions equivalent to an estimated 5.2 million metric tonnes of CO2 each year.

08:05 EDT Trimble and Procter & Gamble collaborating in transportation procurement - Trimble (TRMB) announced a new strategic relationship with Procter & Gamble (PG) to enhance how shippers and carriers partner during the transportation procurement process. This initiative will shape the development of a transportation procurement collaboration platform from Trimble. Procter & Gamble will inform the creation of a platform with a focus on optimizing the procurement of transportation capacity, creating closer shipper and carrier relationships and helping each find the right partners. The platform will also expedite the contracting and onboarding process to increase the velocity of business transactions while enabling more cost-effective movement of freight.

08:04 EDT Aemetis Biogas signs utility pipeline agreement with PG&R - Aemetis (AMTX) announced that its subsidiary Aemetis Biogas has signed the Standard Renewable Gas Interconnection Agreement, or SRGIA, with the Pacific Gas & Electric Company (PCG) and funded the final $1.2M payment for installation of PG&E's interconnection equipment to deliver renewable natural gas, or RNG, into the utility gas pipeline in Q4 2021. The PG&E RNG interconnect equipment has already been fabricated onto modular units that are now scheduled to be delivered to the Keyes plant and installed during the next three months. When the interconnection unit is completed, the RNG produced by the Aemetis Biogas Central Diary Digester Project will be delivered into the Pacific Gas & Electric natural gas pipeline for sale to customers throughout California as transportation fuel. Aemetis has already built and currently operates two dairy biogas digesters, on-site dairy gas upgrading and pressurization facilities, and a four-mile biogas pipeline connecting the dairies to the Aemetis Keyes ethanol plant. The centralized biogas cleanup and onsite RNG fueling facilities at the Keyes plant are currently under construction for completion in Q4 2021, and the construction of 15 additional dairy biogas digesters are in progress for completion during 2022. When fully built out, the planned 52 dairies in the Aemetis biogas project are expected to capture more than 1.4M MMBtu of dairy methane and reduce greenhouse gas emissions equivalent to an estimated 5.2 million metric tonnes of CO2 each year.

08:03 EDT Vaccinex present Phase 2 SIGNAL trial data at EHDN2021 - Vaccinex announced that Maurice Zauderer, PhD, Chief Executive Officer, presented new and promising data from continued analysis of final results of the phase 2 SIGNAL Huntington's Disease Trial at the European Huntington Disease Network Meeting, which was held September 9-11, 2021. On September 10, Dr. Zauderer joined clinical leaders from Roche, Wave, Uniqure and Prilenia to discuss major lessons and continuing plans for clinical trials in Huntington's disease. Dr. Zauderer highlighted new data from the SIGNAL phase 2 trial believed to further support the cognitive benefit of treatment with the pepinemab antibody. People with HD regularly identify cognitive impairment as a major concern that significantly impacts their daily life. Dr. Zauderer also presented subgroup analysis suggesting that the greatest benefit from treatment was detected in patients with moderately advanced disease and discussed how these findings will impact the design of a planned pivotal phase 3 trial, for which the company is actively evaluating potential development partners. During the panel discussion that followed, Dr. Zauderer discussed how he believed the results of SIGNAL and other Vaccinex studies have advanced the company's understanding of pathogenic mechanisms and help to lay a foundation for optimal timing of treatment and identifying rational combination therapies that may result in even greater efficacy in the future. Vaccinex is grateful to the individuals and their families who participated in the SIGNAL phase 2 study and remains committed to advancing this promising potential therapy in both HD and Alzheimer's disease.

08:01 EDT Detroit Thermal enrolls in DTE Energy's MIGreenPower program - Detroit Thermal announced the company's enrollment in DTE's MIGreenPower program. One of the largest voluntary renewable energy programs in the United States, MIGreenPower enables DTE Electric customers to attribute a greater percentage of their energy use to Michigan-made wind and solar beyond the 15% DTE already provides. Detroit Thermal will gradually increase its MIGreenPower enrollment to attribute 100% of its electric usage to renewable resources by 2030. The company's commitment will ultimately offset the carbon dioxide equivalent of greenhouse gas emissions from over 1,000 passenger vehicles driven for a year.

07:48 EDT Draganfly announces exercise of over-allotment option - Draganfly announced that the over-allotment option granted to the underwriters in connection with the Company's previously announced public offering in the United States of common shares was exercised in respect of 95,966 common shares. The exercise of the over-allotment at $4.00 per share produced additional gross proceeds of $383,864, bringing the aggregate gross proceeds to Draganfly under the Offering to $20,383,864, before deducting underwriting discounts and Offering expenses. ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the Offering. The Company intends to use the net proceeds of the Offering, together with existing cash, for general corporate purposes, including to fund ongoing operations, to fund growth initiatives and/or for working capital requirements including the continuing development and marketing of the Company's core products, potential acquisitions and research and development.

07:46 EDT Nice in pact with Canada's BCE to expand NICE CXone for Contact Center service - NICE (NICE) announced an agreement with Bell (BCE), to expand access to NICE CXone for Contact Center as a Service, CCaaS, in Canada. CXone, the world's most comprehensive omnichannel offering in the CCaaS market, will provide Bell customers the industry-leading contact center platform combined with Bell's ultra-fast speed and low latency network that contact centers need for highly flexible, digital-first customer experiences. In today's competitive digital landscape, contact centers play an integral role in fostering customer relationships and building a community of highly engaged brand advocates. Key to establishing these connections is an all-in-one and cloud native omnichannel contact center, which enables the seamless movement between self-service and agent-assisted customer service channels. In fact, the 2020 NICE Customer Experience Transformational Benchmark, Consumer Wave, which surveyed more than 2,500 consumers across the United States, Canada, the United Kingdom and Australia, found that regardless of where they begin an interaction, 94 percent of consumers say they want seamless access to a customer service agent. Further, 83 percent say that they expect to switch to chat, text or phone in the same interaction. CXone, offered by Bell, will help Canada-based contact centers meet and exceed these expectations.

07:42 EDT Oragenics Initiates COVID-19 challenge study testing variations of its vaccine - Oragenics announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study will provide data for several vaccine formulations, using adjuvants specific for both intranasal and intramuscular routes of administration. An assessment of cross-neutralization titers against the Wuhan, Beta and Delta variants of COVID-19 and reduction in the viral load of the Wuhan challenge virus will be used to establish the most promising formulations to advance to human clinical studies. The study is being conducted by the Company's Canadian collaborator with results expected in November. "We are delighted to have begun this important study on schedule and soon after receiving favorable results from our mouse immunogenicity study. We believe the results from this hamster challenge study will further affirm our development strategy for Terra CoV-2. We have particular interest for the intranasal delivery route. The findings from this second preclinical study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration, expected to be made in the first quarter of 2022, to advance the most promising formulations into human clinical studies," said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics.

07:39 EDT Gol Linhas, American Airlines upgrade to exclusive codeshare agreement - GOL Linhas (GOL) has agreed to expand its commercial cooperation with American Airlines (AAL) through an exclusive codeshare agreement for the next three years that will deepen the relationship between the two airlines. As part of the Agreement, GOL will receive an equity investment of $200M from American. Through its exclusivity, the Agreement expands beyond the terms of the existing codeshare partnership between GOL and American, enhancing the travel opportunities for their passengers, the customer experience and the competitive position of GOL on routes connecting North and South America. In place since February 2020, the existing codeshare already represented the largest route network in the Americas, enabling the Company's customers to travel seamlessly to more than 30 destinations in the U.S. The partnership flights currently operate in GOL's hubs in Sao Paulo and Rio de Janeiro, integrating 34 options of Brazilian and international routes, such as Montevideo, in Uruguay.

07:36 EDT Biogen plans to initiate Phase 3b study evaluating higher dose of nusinersen - Biogen announced plans to initiate a global Phase 3b clinical study, ASCEND. The ASCEND study is designed to evaluate the clinical outcomes and assess the safety of a higher dose of nusinersen in children, teens and adults with later-onset spinal muscular atrophy, SMA, following treatment with Evrysdi. "We believe that lower drug exposure may be contributing to less-than-optimal treatment outcomes for some patients treated with Evrysdi. The ASCEND study seeks to understand if nusinersen may address that unmet medical need and will help inform the future of SMA treatment, with the hope of improving patients' outcomes for the long term," said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. The ASCEND protocol has been submitted to the U.S. Food and Drug Administration and is planned to be an approximately 2.5-year study projected to enroll up to 135 later-onset, non-ambulatory individuals with SMA. Individuals enrolled in ASCEND will receive two loading doses of nusinersen 50 mg two weeks apart, followed by a maintenance dose of 28 mg every four months during the study period. Efficacy is planned to be assessed by RULM. The study aims to include children, teens and adults naive to treatment with nusinersen, as well as adults who were previously treated with nusinersen prior to Evrysdi. The company aims for the first eligible patients to be enrolled in 2021.

07:34 EDT Cazoo acquires SMH Fleet Solutions for GBP 70M in cash - Cazoo announced that it has acquired SMH Fleet Solutions , one of the UK's leading vehicle preparation, logistics and storage businesses...This deal will provide Cazoo with one of the most extensive portfolios of vehicle preparation sites and production capabilities in the UK to meet its rapid growth plans. Once fully integrated, Cazoo will have the capacity to recondition and deliver hundreds of thousands of cars per year and store tens of thousands of cars, helping to secure its future requirements and materially de-risk its ability to meet its growth targets. Cazoo has acquired SMH for approximately GBP 70m in cash from LDC and other minority shareholders. The transaction is expected to have a negligible impact on Cazoo's FY2021 operating results.

07:33 EDT Pacira reports preliminary sales of $42.3M for August - Pacira BioSciences reported preliminary unaudited net product sales. EXPAREL net product sales increased 15 percent to $41.4M for the month of August 2021, compared with $36.1M for the prior year. Net product sales of iovera degrees increased 13 percent to $0.9M for the month of August 2021, compared with $0.8M for the prior year. EXPAREL average daily sales for the month of August 2021 were 109 percent of August 2020. The company reports average daily growth rates for EXPAREL to account for differences in the number of selling days per reporting period. EXPAREL selling days were 22 in August 2021 and 21 in August 2020. "We continue to solidify our leadership position in opioid-sparing pain management with EXPAREL now having treated more than nine million patients since launch with penetration increasing across all target market segments," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "EXPAREL utilization continues to significantly outpace the recovery of the elective surgery market, which is facing additional pandemic-related challenges this summer with regional surges in delta variant cases, staffing shortages, and surgical fatigue from care teams addressing significant procedure backlogs. We expect these variables to subside and the fourth quarter to reflect improving market dynamics. From a competitive standpoint, we have not experienced impact from new market entrants and EXPAREL remains extremely well positioned given its broad efficacy label that spans infiltration, field blocks and brachial plexus nerve block. In addition, a pristine safety profile and proven ability to reliably facilitate surgical migration to outpatient sites of care continue to be hallmarks of EXPAREL adoption across pediatric and adult settings. Looking ahead, we remain confident in our ability to achieve our five-year objectives and deliver topline annual growth in the high teens with operating margins that exceed 50 percent by the end of our planning period."

07:33 EDT OpGen announces data from clinical study using Unyvero HPN panel - OpGen announced clinical data from an investigator-initiated and driven prospective randomized controlled multicenter study. Data on the Unyvero HPN was presented at the virtual European Respiratory Society conference on September 7, 2021, and presented during a webinar held on September 14, 2021. The webinar titled "Multiplex Bacterial PCR in Bronchoalveolar Lavage - Does It Impact Inappropriate Antibiotic Use?" described the study which assessed the clinical utility and impact of the Unyvero panel in hospitalized adult patients with suspicion of pneumonia and a clinical indication for bronchoscopy and at risk for infection with Gram-negative bacteria. The primary study endpoint was duration of inappropriate antibiotic therapy. Summary of the study results based on the primary endpoint and findings from several other measured metrics: Inappropriate antibiotic treatment was significantly shorter in the PCR group - Unyvero decreased the average duration of inappropriate antibiotic therapy from 86 hours in the control group to 47 hours in the PCR intervention group; duration of antibiotic therapy altogether was reduced by 22.5% in the PCR group; probability of avoiding inappropriate antibiotic therapy was 3 times higher in the patient group that was diagnosed by Unyvero; clinical stability were assessed to determine if decreasing the amount of antibiotics or reduction in use of broad-spectrum antibiotics in the intervention group worsened patient outcomes, and the findings suggested that there was no significant difference in the two randomized groups; Gram-negative rods in BAL were detected more commonly by Unyvero PCR than conventional culture - 45 bacteria in 39 patients vs. 32 bacteria in 33 patients, respectively. The study concluded that "The results of Unyvero combined with antibiotic stewardship is efficient and safe in decreasing time on inappropriate antibiotic therapy in hospitalized patients with pneumonia at risk for Gram-negative rods."

07:20 EDT Seres Therapeutics achieves enrollment in ECOSPOR IV trial - Seres Therapeutics announced it has achieved enrollment of 300 subjects with the ECOSPOR IV open-label study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection. The target enrollment of a minimum of 300 subjects for the SER-109 safety database was reached in conjunction with a prior completed Phase 3 study, ECOSPOR lll. Seres is required by the FDA to demonstrate safety of SER-109 in at least 300 subjects who have received the dose to be commercialized, consistent with standard FDA guidance, with a 24-week follow-up period, to support a biologics license application submission. Seres plans to close enrollment in the open-label study in the coming weeks and will engage with the FDA on initiation of an expanded access program by the end of the year. Seres intends to seek agreement with the FDA to begin a rolling submission of the BLA for SER-109 in the first half of 2022 and finalize the submission with data from the safety database in mid-2022.

07:17 EDT Uranium Royalty purchasing 300,000 pounds of U3O8 - Uranium Royalty is entering into contracts for three additional spot purchases totaling 300,000 pounds of U3O8 at an average cost of $38.17 per pound U3O8. Deliveries are scheduled for September/October and will be accomplished through book transfers to URC's storage account at Cameco Corporation's Fuel Services facilities in Ontario, Canada. This acquisition is fully funded with cash on hand. As of September 14, URC has C$80M in cash, marketable securities and physical uranium. Following completion of these deliveries, URC will hold a physical inventory of 648,068 pounds U3O8 at a weighted average cost of $33.10 per pound. The latest Trade Tech daily spot price is at $45.00 per pound as of September 14, leading to an increase in the net realizable value of URC's physical uranium holdings by $7.7M. The company believes that the global mega-trend towards de-carbonization is providing a major catalyst for carbon-free, safe, and reliable nuclear energy.

07:13 EDT BeiGene receives accelerated approval for Brukinsa from FDA - BeiGene announced that Brukinsa has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.

07:12 EDT Actinium Pharmaceuticals completes enrollment in Phase 3 SIERRA trial of Iomab-B - Actinium Pharmaceuticals announced that it has completed enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B, an Antibody Radiation Conjugate comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131. The SIERRA trial is a 150-patient, randomized and controlled study conducted at 24 leading bone marrow transplant centers in the United States and Canada. SIERRA is the only randomized Phase 3 trial to offer bone marrow transplant to patients with active, relapsed or refractory acute myeloid leukemia age 55 and above, which is the only curative treatment option for this patient population. Actinium expects to present data updates from the SIERRA trial in the fourth quarter and to announce topline data for the primary endpoint of six-month durable Complete Remission in mid-2022. These data are expected to support registration of a Biologics License Application for Iomab-B.

07:12 EDT RingCentral granted unified license in India - RingCentral announced that it has been granted a unified license that will enable the company to provide its Unified Communications as a Service, or UCaaS, and Contact Center as a Service, or CCaaS, solutions in India, and will make RingCentral the first global cloud provider to offer fully compliant voice and other unified cloud communications in the country. RingCentral will offer global organizations solutions globally, including India.

07:11 EDT Lantronix announces creation of Advisory Board - Lantronix announced that it has created an Advisory Board to enhance the Company's strategic development, acquire additional expertise of industry leaders, and enable former members of the Board or the Company's management to continue to make significant contributions to the Company. Bernhard Bruscha, Lantronix's current Chair of the Board, has decided to retire November 2021 and not to stand for re-election to the Company's Board of Directors at the Company's 2021 annual meeting of stockholders, currently scheduled for November 9, 2021. He will continue to support the Company by agreeing to serve as the Advisory Board's first member and Chair, effective November 9, 2021. In addition, Lantronix announced that it intends to select Dr. Heidi Nguyen as a nominee for election by stockholders at the Annual Meeting. Dr. Nguyen, as Vice President of TL Investment, GmbH, is expected to continue to represent TL Investment, GmbH as a continuing major stockholder of Lantronix. Dr. Nguyen is Mr. Bruscha's spouse.

07:09 EDT Autolus Therapeutics appoints John Johnson as non-executive chairman - Autolus Therapeutics (AUTL) announced that John Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021. Dr. Martin Murphy, who previously served as chairman, will continue to serve as a non-executive Board member. Johnson brings to Autolus more than 30 years of experience in the life science industry. He is currently CEO and a director of Strongbridge Biopharma (SBBP).

07:09 EDT LiveXLive Media to change name to 'LiveOne,' spin out pay-per-view business - LiveXLive Media announced that it plans to change its name to "LiveOne, Inc." as part of an overall rebranding of the company and its business units, subject to obtaining applicable approvals and consents. LiveXLive expects to change its NASDAQ stock symbol to "LVO" in the coming weeks. No actions are needed by LiveXLive's stockholders with respect to the planned name change and stock symbol change. Separately, LiveXLive also announced its intention to spin-out its existing pay-per-view business as a separate public company and its plan to distribute a portion of the new company's equity to LiveXLive's stockholders, anticipated to take place by March 31, 2022, in each case subject to obtaining applicable approvals and consents and compliance with applicable rules and regulations and public market trading and listing requirements.

07:08 EDT Glaukos enters settle agreement with Ivantis - Glaukos announced that it has entered into a settlement agreement with Ivantis, agreeing to terminate the patent infringement lawsuit Glaukos initiated on April 14, 2018 in the U.S. District Court for the Central District of California, Southern Division, concerning Ivantis' Hydrus Microstent. Under the agreement, Ivantis will pay Glaukos $60M, $30M of which will be paid by December 31 and the other $30M to be paid by December 31, 2022. Ivantis will also pay Glaukos a 10% ongoing royalty through April 26, 2025, based on Ivantis' Hydrus Microstent U.S. sales and any international sales supplied out of the U.S. Further, the parties have agreed to mutual licenses and covenants not to sue on the Hydrus and iStent technologies. In accordance with the settlement, the parties will submit a joint request to stay the pending litigation, which had been scheduled for trial beginning on September 28 and dismiss it upon receipt of the first upfront payment.

07:07 EDT Landos Biopharma to present results of LABP-104 in Lupus as ACR - Landos Biopharma, a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, announced that it will present preclinical data of LABP-104, an oral, small-molecule LANCL2 agonist, in Systemic Lupus Erythematosus as an oral presentation at the upcoming American College of Rheumatology, or ACR, Convergence 2021. The meeting will be held virtually from November 3-10, 2021. "These novel findings support the potential therapeutic efficacy of LABP-104 in SLE, along with the power of our LANCE platform to discover and validate novel targets at the intersection of immunity and metabolism. Altogether, they highlight the breadth and depth of our expansible inflammation and immunology pipeline," said Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos. "Our Phase 2 trial with omilancor in ulcerative colitis illustrated the important immunoregulatory mechanisms of the Lanthionine Synthetase C-Like 2 pathway including enhancing regulatory T cell function. With these new data in lupus, we have further validation of LABP-104's therapeutic potential to activate this pathway's ability to intercept and possibly reverse the complex cascade of immunological events that lead to disease and pathology in lupus patients." Landos expects to enter Phase 1 clinical testing of LABP-104 as an oral therapeutic candidate for lupus during the fourth quarter of 2021, further expanding the company's deep inflammation and immunology pipeline. Presentation title: Therapeutic efficacy of LABP-104, an oral LANCL2 agonist, for the treatment of systematic lupus erythematosus. Highlights: Oral treatment with LABP-104 protected against worsening from baseline in proteinuria grade in greater than 90% of mice, improved proteinuria grade in roughly 50% of mice and reduced anti-nuclear antibody levels by three-fold; reduced overall histological score in the kidneys; and significantly reduced the production of interferon alpha in human peripheral blood mononuclear cells from SLE patients in response to general, TLR7 and CpG oligonucleotide stimuli.

07:05 EDT Archer Daniels unveils flavor production facility in China - ADM unveiled the ADM Food Technology, a fully automated flavor production facility situated in Pinghu, Zhejiang Province, China. The 27,000+ square meter flavor production facility is located within an hour of Shanghai.

07:04 EDT Marimed announces COVID-19 protocols for annual shareholder meeting - MariMed announced health and safety protocols that are being implemented at the Company's annual meeting, to be held on September 23, 2021, 10am ET at the Hilton Boston/Dedham in Dedham, MA. In order to protect everyone in attendance, the protocols include: Only stockholders of the Company will be admitted to the meeting. Record stockholders will be confirmed from the Company's stockholder records. If a stockholder holds his or her shares in a brokerage account, a copy of a recent statement reflecting the position will be required. To gain admittance to the meeting, each stockholder must present proof of vaccination, or a negative COVID-19 test result completed within 72 hours of the meeting time. All attendees will be required to wear a mask covering their nose and mouth for the duration of the meeting. No food or beverages will be permitted in the meeting. No exceptions will be made to the foregoing protocol.

07:04 EDT CFGI announces investment from CVC Capital Partners Fund VIII - CFGI announced that funds advised by CVC Capital Partners have agreed to acquire a significant interest in the company, valuing CFGI at approximately $1.85B. All existing shareholders are reinvesting in the transaction in partnership with CVC, including funds managed by global investment firm Carlyle, Co-Founders and Co-CEOs Nick Nardone and Shane Caiazzo, and the partners of CFGI. Additional terms of the transaction were not disclosed.

07:03 EDT Ford, Argo Ai and Walmart to launch autonomous vehicle delivery service - Ford (F), Argo AI and Walmart (WMT) are working together to launch an autonomous vehicle delivery service in Miami, Austin, Texas, and Washington, D.C., Walmart's first multi-city autonomous delivery collaboration in the U.S. The last mile delivery service will use Ford self-driving test vehicles equipped with the Argo AI Self-Driving System to deliver Walmart orders to customers. The multi-city service will enable Walmart customers to place orders of groceries and other popular items online for door-to-door autonomous delivery directly to customers' homes. The commercial service will be available to Walmart customers within defined service areas of the three markets and will expand over time, with initial integration testing slated to begin later this year.

07:03 EDT Cathie Wood's ARK Investment bought 235.6K shares of Zoom Video on Tuesday

06:57 EDT Wex signs new fleet card agreement with State of Minnesota - Wex has been awarded and entered into the state-wide fleet card contract with the State of Minnesota through the NASPO ValuePoint Master Agreement. NASPO ValuePoint is the cooperative purchasing arm of the National Association of State Procurement Officials. With the recent signings of additional NASPO participants Washington, Oregon, Colorado, Wisconsin, Arizona and Connecticut, WEX now has 34 state government contracts and approximately 1.2 million cards issued to state, federal and local government entities.

06:51 EDT Pentair enters definitive agreement to acquire Pleatco for $255M in cash - Pentair announced that it has entered into a definitive agreement to acquire Pleatco, a manufacturer of water filtration and clean air technologies for pool, spa and industrial air customers. Pleatco is a current portfolio company of Align Capital Partners, a private equity firm with investment teams in Dallas, TX and Cleveland, OH. The planned acquisition of Pleatco provides Pentair an expanded range of replacement filter products to be sold through Pentair's existing Pool and Spa distribution channels as well as through Pleatco's distribution channels. Total consideration for the transaction is approximately $255M in cash, subject to customary adjustments. Pentair expects Pleatco to generate approximately $95M of annual revenue in 2021. The transaction is expected to be accretive in its first full year. The acquisition is anticipated to be completed in the fourth quarter, subject to customary closing conditions and necessary regulatory approvals, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

06:47 EDT G1 Therapeutics to hire new supplemental Cosela sales force - G1 Therapeutics announced that it will hire and train a 15-person oncology sales force to supplement the Boehringer Ingelheim oncology commercial team. The expansion will allow G1 to target top tier accounts in order to accelerate sales activities and help maximize the adoption of Cosela. The new G1 sales representatives will supplement the existing Boehringer Ingelheim oncology commercial team. G1 entered into a three-year co-promotion agreement with Boehringer Ingelheim to collaborate on the commercialization of Cosela for its first indication in ES-SCLC.

06:36 EDT Trimble announces beta launch of SketchUp for iPad - Trimble announced the beta launch of SketchUp for iPad, a new product that enables interior designers, architects, engineers and construction professionals to create, edit and collaborate on SketchUp models from anywhere, at any time. SketchUp for iPad is an bridge for architects and designers looking to move from paper and pencil to creating 3D models using an iPad, iPad Air, iPad mini, iPad Pro, Apple Pencil, mouse and keyboard, or multitouch gestures.

06:34 EDT Infosys, SAP collaborate to provide business process transformation-as-a-service - Infosys (INFY) announced a strategic collaboration with SAP (SAP) to provide business process transformation-as-a-service to enterprises.

06:33 EDT Capital One reports August net charge-offs 1.54% vs. 1.45% last month - Reports August 30-plus day delinquencies 1.79% vs. 1.71% last month.

06:31 EDT Synchrony reports August charge-off rate 2.59% vs. 2.24% last month - Reports August 30-plus day delinquencies 1.33% vs. 1.37% last month.

06:11 EDT Theravance Biopharma to reduce headcount by 75% - Theravance Biopharma announced strategic actions to focus on leveraging its expertise in developing and commercializing respiratory therapeutics in order to maximize shareholder value. These changes follow a scenario planning exercise led by the board and management with the assistance of outside advisors. In order to implement this plan, Theravance Biopharma will immediately initiate a significant cost reduction program. Headcount will be reduced by approximately 75%, an estimated 270 positions, with approximately 75% of the reduction expected to be completed in November and the remainder to be completed in February 2022. The company has also decided to reduce the size of its board, and is announcing the resignations from the board of two long-term directors: George Whitesides and Robert Gunderson, effective immediately.

06:09 EDT Theravance Biopharma reports ampreloxetine study did not meet primary endpoint - Theravance Biopharma announced top-line results from a Phase 3 randomized, double-blind, placebo-controlled multi-center Phase 3 study assessing the safety and efficacy of ampreloxetine compared to placebo for the treatment of symptomatic neurogenic orthostatic hypotension, or nOH. The study did not meet its primary endpoint. The majority of treatment-related adverse events were mild or moderate in severity. Serious adverse events occurred in two patients on placebo and four on ampreloxetine and none were considered related to the study drug; no deaths were reported. There was no signal for supine hypertension. The company plans to present the results at a future scientific forum. In light of these results, the company will be determining the appropriate next steps for Study 0170 and Study 0171; clinical trial sites will be notified accordingly.

06:02 EDT CAE selected by BETA to design, develop ALIA eVTOL training program - CAE announced that BETA Technologies selected CAE as its partner of choice to design and develop its pilot and maintenance technician training program for the ALIA eVTOL aircraft. CAE will leverage its decades of training expertise to develop a full suite of digitally integrated curriculum and courseware solutions for the aviation workforce. The new training program will be built from the ground-up, in parallel with BETA's aircraft certification journey, taking into account the operational and mission specific inputs for this aircraft.

05:27 EDT Ecopetrol receives COP 3.67B fine from ANLA - Ecopetrol reported that it was notified through Resolution 01613 that the National Environmental Licensing Authority, or ANLA, had fined Ecopetrol in the sum of COP 3.67B. This sanction originated from works carried out in the CPO09 Exploratory Drilling Area project located in the municipality of Acacias, Meta Department, because ANLA considered that a bridge was not contemplated in the environmental license and that locations were built at a shorter distance to the preservation areas of the Cano Lejia and Cano NN water resources. Ecopetrol abides by and respects the decisions of ANLA. However, the company said its actions have always been framed in compliance with current legal regulations, so it will make use of the appropriate legal resources in order to obtain the revocation of this decision.

05:17 EDT Biophytis receives recommendation from DMC to continue COVA study as is - Biophytis announced the recommendation by the Data Monitoring Committee, or DMC, to continue the Phase 2-3 COVA study without any modification of the protocol, after the interim efficacy data were found in the promising zone in the Interim Analysis 2 based on 155 COVID-19 patients hospitalized with respiratory failure. This recommendation completes previous safety evaluation performed by DMC last August that confirmed the safety profile of Sarconeos.

05:04 EDT Ideanomics to increase stake in Energica to 70% - Ideanomics announced it has entered into an agreement to launch a voluntary conditional tender offer in concert with the Founders of Energica for shares of Energica, a manufacturer and distributor of 100% battery-powered electric motorcycles, pursuant to which Ideanomics plans to increase its investment in Energica to approximately 70%. The Energica Founders shall continue to own 29% of Energica. The transaction is subject to regulatory approval, and other customary closing conditions.